Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Trials evaluating the efficacy of CD20 CAR-T cell therapy in WM and CNS lymphoma

Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, briefly describes an ongoing multi-center clinical trial investigating the efficacy and safety of CD20 CAR-T cell therapy in patients with Waldenström’s macroglobulinemia (WM) and CNS lymphoma. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.